FDA Sued Over 180-Day Exclusivity Determination for Generic NAMENDA XR; It’s All About the “Causal Connection”

FDA Sued Over 180-Day Exclusivity Determination for Generic NAMENDA XR; It’s All About the “Causal Connection”

Submitted by admin on January 31, 2017 - 9:49am
Source: 
FDA Law Blog
News Tags: 
FDA
Namenda XR
generica
Amneal
exclusivity
Headline: 
FDA Sued Over 180-Day Exclusivity Determination for Generic NAMENDA XR; It’s All About the “Causal Connection”

Do Not Allow Advertisers to Use My Personal information